CANC holdings
All 57 positions of Tema Oncology ETF.
Positions
57
Top 10 weight
42.9%
Effective holdings
32.6
1 / sum of squared weights
In stocks
99.0%
In bonds
0.0%
Outside the US
19.2%
Asset mix
Sectors
85% of stocks classifiedCountries
Holdings
| # | Holding | Type | Weight | Value | Shares / par | Country |
|---|---|---|---|---|---|---|
| 1 | RVMDRevolution Medicines, Inc. Common Stock | Equity | 7.73% | $14M | 86,450 | US |
| 2 | LLYEli Lilly & Co. | Equity | 4.82% | $8.5M | 7,684 | US |
| 3 | RHHBYROCHE HOLDING LTD S/ADR | Equity | 4.21% | $7.4M | 141,653 | CH |
| 4 | COGTCogent Biosciences, Inc. Common Stock | Equity | 4.10% | $7.2M | 206,419 | US |
| 5 | Novartis AG | Equity | 4.03% | $7.1M | 47,020 | CH |
| 6 | IMNMImmunome, Inc. | Equity | 3.91% | $6.9M | 315,648 | US |
| 7 | CELCCelcuity Inc. Common Stock | Equity | 3.58% | $6.3M | 47,450 | US |
| 8 | MRKMerck & Co., Inc. | Equity | 3.57% | $6.3M | 52,978 | US |
| 9 | AstraZeneca PLC | Equity | 3.54% | $6.2M | 33,501 | GB |
| 10 | NUVLNuvalent, Inc. Class A Common Stock | Equity | 3.37% | $5.9M | 53,763 | US |
| 11 | BMYBristol-Myers Squibb Co. | Equity | 3.30% | $5.8M | 101,680 | US |
| 12 | LEGNLegend Biotech Corporation American Depositary Shares | Equity | 2.99% | $5.3M | 194,092 | US |
| 13 | ABBVABBVIE INC. | Equity | 2.81% | $4.9M | 22,700 | US |
| 14 | EXELExelixis Inc | Equity | 2.78% | $4.9M | 96,885 | US |
| 15 | BBIOBridgeBio Pharma, Inc. Common Stock | Equity | 2.75% | $4.8M | 73,191 | US |
| 16 | JNJJohnson & Johnson | Equity | 2.55% | $4.5M | 19,900 | US |
| 17 | CGONCG Oncology, Inc. Common stock | Equity | 2.43% | $4.3M | 68,702 | US |
| 18 | GMABGenmab A/S ADS | Equity | 2.37% | $4.2M | 158,861 | DK |
| 19 | IDYAIDEAYA Biosciences, Inc. Common Stock | Equity | 2.27% | $4.0M | 135,847 | US |
| 20 | AMGNAmgen Inc | Equity | 2.11% | $3.7M | 11,019 | US |
| 21 | ZLABZai Lab Limited American Depositary Shares | Equity | 1.98% | $3.5M | 196,972 | CN |
| 22 | ONCBeOne Medicines Ltd. American Depositary Shares | Equity | 1.88% | $3.3M | 11,505 | US |
| 23 | ZYMEZymeworks Inc. | Equity | 1.51% | $2.7M | 105,615 | US |
| 24 | ELVNEnliven Therapeutics, Inc. Common Stock | Equity | 1.31% | $2.3M | 58,197 | US |
| 25 | RLAYRelay Therapeutics, Inc. Common Stock | Equity | 1.28% | $2.3M | 161,076 | US |
| 26 | HALOHalozyme Therapeutics, Inc. | Equity | 1.23% | $2.2M | 32,598 | US |
| 27 | SMMTSummit Therapeutics Inc. Common Stock | Equity | 1.21% | $2.1M | 121,097 | US |
| 28 | RCUSArcus Biosciences, Inc. | Equity | 1.20% | $2.1M | 83,140 | US |
| 29 | GILDGilead Sciences Inc | Equity | 1.12% | $2.0M | 14,692 | US |
| 30 | Immatics NV | Equity | 1.12% | $2.0M | 171,499 | DE |
| 31 | First American Treasury Obliga | Cash | 1.09% | $1.9M | 1,920,309 | US |
| 32 | ERASErasca, Inc. Common Stock | Equity | 1.08% | $1.9M | 147,828 | US |
| 33 | NUVBNuvation Bio Inc. | Equity | 1.07% | $1.9M | 395,313 | US |
| 34 | ANABAnaptysBio, Inc. Common Stock | Equity | 0.99% | $1.7M | 31,270 | US |
| 35 | UroGen Pharma Ltd | Equity | 0.93% | $1.6M | 58,518 | US |
| 36 | GHGuardant Health, Inc. Common Stock | Equity | 0.81% | $1.4M | 10,986 | US |
| 37 | SNDXSyndax Pharmaceuticals, Inc. | Equity | 0.80% | $1.4M | 72,212 | US |
| 38 | CRVSCorvus Pharmaceuticals, Inc. | Equity | 0.76% | $1.3M | 108,477 | US |
| 39 | REGNRegeneron Pharmaceuticals Inc | Equity | 0.75% | $1.3M | 2,138 | US |
| 40 | AVBPArriVent BioPharma, Inc. Common Stock | Equity | 0.73% | $1.3M | 42,744 | US |
| 41 | Chugai Pharmaceutical Co Ltd | Equity | 0.67% | $1.2M | 23,697 | JP |
| 42 | IOVAIovance Biotherapeutics, Inc. Common Stock | Equity | 0.65% | $1.1M | 280,048 | US |
| 43 | INBXInhibrx Biosciences, Inc. Common Stock | Equity | 0.60% | $1.1M | 10,170 | US |
| 44 | OLMAOlema Pharmaceuticals, Inc. Common Stock | Equity | 0.60% | $1.1M | 79,759 | US |
| 45 | CGEMCullinan Therapeutics, Inc. Common Stock | Equity | 0.59% | $1.0M | 62,826 | US |
| 46 | NTRANatera, Inc. Common Stock | Equity | 0.54% | $947K | 4,238 | US |
| 47 | TRAXFirst Tracks Biotherapeutics, Inc. Ordinary Shares | Equity | 0.53% | $932K | 58,419 | US |
| 48 | IMCRImmunocore Holdings plc American Depositary Shares | Equity | 0.51% | $891K | 30,849 | GB |
| 49 | BBOTBridgeBio Oncology Therapeutics, Inc. Common Stock | Equity | 0.48% | $837K | 93,339 | US |
| 50 | CTMXCytomX Therapeutics, Inc. | Equity | 0.47% | $824K | 228,987 | US |
| 51 | HCMHUTCHMED (China) Limited American Depositary Shares | Equity | 0.44% | $777K | 67,823 | HK |
| 52 | ARVNArvinas, Inc | Equity | 0.43% | $755K | 84,124 | US |
| 53 | JANXJanux Therapeutics, Inc. Common Stock | Equity | 0.43% | $752K | 51,522 | US |
| 54 | ANLAdlai Nortye Group Ltd. American Depositary Shares | Equity | 0.30% | $530K | 44,354 | KY |
| 55 | TYRATyra Biosciences, Inc. Common Stock | Equity | 0.30% | $527K | 15,780 | US |
| 56 | ORICOric Pharmaceuticals, Inc. Common Stock | Equity | 0.28% | $490K | 57,977 | US |
| 57 | SLSSELLAS Life Sciences Group, Inc. Common Stock | Equity | 0.22% | $379K | 40,702 | US |
Find which other funds hold a stock by opening it and choosing "ETFs holding".
Position changes between reports
| Action | Holding | Weight before | Weight after | Shares vs flows | Between reports |
|---|---|---|---|---|---|
| Exit | ACLXArcellx Inc | 3.44% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | BBIOBridgebio Pharma Inc | 4.75% | 2.75% | −41.4% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | LEGNLegend Biotech Corp | 1.37% | 2.99% | +54.0% | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | RVMDRevolution Medicines Inc | 6.29% | 7.73% | −19.7% | Feb 28, 2026 → May 31, 2026 SEC |
| New position | ELVNEnliven Therapeutics Inc | — | 1.31% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | IMNMImmunome Inc | 2.67% | 3.91% | +47.9% | Feb 28, 2026 → May 31, 2026 SEC |
| New position | Immatics NV | — | 1.12% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | CELCCelcuity Inc | 2.47% | 3.58% | +22.9% | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | AstraZeneca PLC | 4.63% | 3.54% | −13.1% | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | NRIXNurix Therapeutics Inc | 0.97% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | SNDXSyndax Pharmaceuticals Inc | 1.73% | 0.80% | −48.1% | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | BMYBristol-Myers Squibb Co | 4.22% | 3.30% | −13.9% | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | DAWNDay One Biopharmaceuticals Inc | 0.81% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | COGTCogent Biosciences Inc | 3.29% | 4.10% | +39.7% | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | ARGXArgenx SE | 0.80% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | GMABGenmab A/S | 3.13% | 2.37% | −14.3% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | CGONCG oncology Inc | 1.69% | 2.43% | +37.1% | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | TERNTerns Pharmaceuticals Inc | 0.74% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| New position | IOVAIovance Biotherapeutics Inc | — | 0.65% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | Chugai Pharmaceutical Co Ltd | 1.28% | 0.67% | −29.2% | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | XNCRXencor Inc | 0.61% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | RCUSArcus Biosciences Inc | 0.59% | 1.20% | +65.7% | Feb 28, 2026 → May 31, 2026 SEC |
| New position | INBXInhibrx Biosciences Inc | — | 0.60% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | EXELExelixis Inc | 2.19% | 2.78% | +11.4% | Feb 28, 2026 → May 31, 2026 SEC |
| New position | TRAXFirst Tracks Biotherapeutics I | — | 0.53% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | ZLABZai Lab Ltd | 1.46% | 1.98% | +48.8% | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | GLUEMonte Rosa Therapeutics Inc | 0.51% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | IDYAIdeaya Biosciences Inc | 1.80% | 2.27% | +39.4% | Feb 28, 2026 → May 31, 2026 SEC |
| New position | BBOTBridgeBio Oncology Therapeutic | — | 0.48% | — | Feb 28, 2026 → May 31, 2026 SEC |
| New position | CTMXCytomX Therapeutics Inc | — | 0.47% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Exit | CMPXCompass Therapeutics Inc | 0.45% | — | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | ABBVAbbVie Inc | 2.43% | 2.81% | +24.4% | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | ERASErasca Inc | 1.45% | 1.08% | −20.1% | Feb 28, 2026 → May 31, 2026 SEC |
| New position | ANLAdlai Nortye Ltd | — | 0.30% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | TYRATyra Biosciences Inc | 0.59% | 0.30% | −49.2% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | OLMAOlema Pharmaceuticals Inc | 0.86% | 0.60% | +29.1% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | GILDGilead Sciences Inc | 0.86% | 1.12% | +45.1% | Feb 28, 2026 → May 31, 2026 SEC |
| New position | SLSSELLAS Life Sciences Group Inc | — | 0.22% | — | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | CRVSCorvus Pharmaceuticals Inc | 0.94% | 0.76% | +21.0% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | RHHBYRoche Holding AG | 4.06% | 4.21% | +19.1% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | NTRANatera Inc | 0.40% | 0.54% | +27.3% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | CGEMCullinan Therapeutics Inc | 0.46% | 0.59% | +22.3% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | ONCBeOne Medicines Ltd | 1.78% | 1.88% | +17.6% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | ARVNArvinas Inc | 0.38% | 0.43% | +70.0% | Feb 28, 2026 → May 31, 2026 SEC |
| Decrease | UroGen Pharma Ltd | 0.91% | 0.93% | −20.2% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | ORICORIC Pharmaceuticals Inc | 0.30% | 0.28% | +50.0% | Feb 28, 2026 → May 31, 2026 SEC |
| Increase | JNJJohnson & Johnson | 2.53% | 2.55% | +12.1% | Feb 28, 2026 → May 31, 2026 SEC |
Share-count changes are measured after removing what creations and redemptions explain.
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.